---
document_datetime: 2023-09-21 21:42:22
document_pages: 50
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rasilez-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: rasilez-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 89.2977228
conversion_datetime: 2025-12-26 11:36:42.869139
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rasilez

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued² / amended on   | Product Information affected3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| IAIN/0131            | B.I1.b.2.c.1-Change to importer,batch release arrangements and quality control testing of the FP - Replacementoradditionofamanufacturer responsible for importation and/or batch release - Not including batch control/testing | 23/02/2023                          |                                            | Annex II and PL                 |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0130          | A.5.b-Administrative change-Change in the name and/oraddressof amanufacturer/importerof the finishedproduct,including quality control sites (excludingmanufacturerforbatchrelease)                                                                                                                                                                                                                                                                                                                                                       | 13/01/2023   | n/a        |                                  |                                |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|--------------------------------|
| IB/0129          | C.1.11.z-Introduction of,or change(s) to, the obligations and conditions of a marketing authorisation,including the RMP-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                   | 25/11/2022   | n/a        |                                  |                                |
| PSUSA/89/20 2109 | PeriodicSafetyUpdateEUSingleassessment- aliskiren，aliskiren/hydrochlorothiazide                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/06/2022   | n/a        |                                  | PRACRecommendation-maintenance |
| IA/0128/G        | This was an applicationfor a group of variations. B.II.e.1.b.3-Changein immediatepackaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging containerwithoutacompletedeletionofastrength orpharmaceuticalform A.7-Administrativechange-Deletion of manufacturingsites A.4-Administrativechange-Changeinthename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS,startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovel excipient | 28/01/2022   | 03/02/2023 | SmPC, Annex II, Labelling and PL |                                |
| IA/0126          | A.4-Administrativechange-Changeinthename and/or address of a manufacturer or an ASMF holder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor                                                                                                                                                                                                                                                                                                                                                       | 15/04/2021   | n/a        |                                  |                                |

<div style=\"page-break-after: always\"></div>

|           | manufacturerof anovel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0125/G | This was an applicationfor a group of variations. B.I.b.2.e-Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.b.1.a-Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b-Replacement or addition of a manufacturingsitefortheFp-Primarypackaging site B.II.b.1.e-Replacementor addition of a manufacturing sitefor theFp-Sitewhereany manufacturing operation(s) take place, except batch- release,batchcontrol,primaryandsecondary packaging,for non-sterile medicinalproducts B.II.b.2.a-Change to importer,batch release arrangements andqualitycontrol testingof theFP- Replacement/additionofasitewherebatch control/testing takes place B.II.b.3.a - Change in the manufacturing process of thefinishedorintermediateproduct-Minorchange in themanufacturingprocess B.II.b.3.a-Change in the manufacturing process of thefinished orintermediate product-Minor change in themanufacturingprocess | 22/10/2020 | n/a |

<div style=\"page-break-after: always\"></div>

| - Other changes to a test procedure (including replacement or addition) B.II.e.2.z-Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementor additionofasitewhere batchcontrol/testing takesplace   |            |     |              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------|
| This was an applicationfor a variationfollowing a worksharingprocedure accordingtoArticle20of CommissionRegulation(EC)No1234/2008. B.I.d.1.a.4-Stability of AS -Change in the re-test period/storage period-Extension or introduction of a re-testperiod/storageperiodsupportedbyrealtime                                                                                                                                                    | 28/05/2020 | n/a | WS/1818 data |
| This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. C.I.11.b-Introduction of, or change(s) to, the obligationsandconditionsofamarketing authorisation,including theRMP-Implementation of change(s)which require tobefurthersubstantiated by newadditional data tobesubmittedby theMAH where significant assessment is required                             | 05/09/2019 | n/a | WS/1581      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PSUSA/89/20 1809   | PeriodicSafetyUpdateEUSingleassessment- aliskiren,aliskiren/hydrochlorothiazide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 11/04/2019   | n/a        |                       | PRACRecommendation-maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1371            | Thiswas an applicationfor avariationfollowing a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Update ofsections4.4,4.8and5.1 of theSmPCof RasilezandRasilez/HCTZSmPCinordertoreflect theresultsfrompaediatricstudyCSPP100A2365E2 (amulticenter,52to104weekextensionstudyto evaluatethelongtermgrowthanddevelopmentof pediatric hypertensive patients 6-17 years of age treatedpreviouslywith aliskiren)provided asperthe requirement of article 46. In addition,theMarketing authorisationholder (MAH)tooktheopportunity toimplementminor amendments in sections 4.2,4.3,4.5 and 4.7,5.2 of RasilezSmPCandpackageleafletinalignmentwith Rasilez/HCTZproduct information,as well as an editorial change inAnnexII.Moreover,section 4.2 of theRasilez/HCTZSmPChasbeenupdated tocross refer to sections 4.8,5.1,and5.2in alignment with RasilezSmPC. C.I.4-Change(s)in theSPC,Labelling orPLdue to newquality,preclinical,clinical orpharmacovigilance data | 18/10/2018   | 09/10/2019 | SmPC, Annex II and PL | Study CSPP100A2365E2 extension of the core study (CSPP100A2365E),evaluated thelong-termsafetyinterms of growth and development of children 6-17 years of age withhypertension(primary orsecondary)at baseline in the corestudy,previouslytreatedwithaliskiren.Overall,106 paediatric patients aged 6 to 17 years with hypertension (primaryorsecondary)atbaselineinthecorestudy, previouslytreatedwithaliskiren,wereenrolledinthis52to 104weekoff-therapynon-interventionalobservational extension study. Thelong-termsafetyisevaluated intermsofgrowth and development,throughheight andweightmeasurement, withaddedneurocognitive andrenalfunctionevaluations asfollow-upmeasuresperformedonlyinpatientswith secondaryhypertension(19 patients). Intheprimaryanalysis,therewere nostatistically significant differences in the mean changes in weight, height,orBMIbetween the treatmentgroups(aliskiren comparedtotheenalapril)frombaselinetolongtermvisit (Week 104). Inpatients after104 weeks (Week156),there were LS meandecreasesfromBaselineinweightandBMIinboth treatmentgroups,withaslightlylargerdecreaseinthe aliskirencomparedtotheenalapril treatmentgroup.There wasagreaterLSmeanincreasefromBaselineinheight after104weeks(Week156)insecondaryhypertension patientscompared totheincreaseobservedafter52weeks (Week104)inprimaryhypertensionpatients,which is |

<div style=\"page-break-after: always\"></div>

|                  |                                                                                                                                                                                                                                                                                                                                                                                   |            |            |      | expected inthese growingpaediatricpatients. Results ofthe neurocognitive assessments,performed only inpatientswithsecondaryhypertension,showedsome improvementsinmost of thetestscores,withno meaningful difference between the treatment groups.   |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0121/G        | Thiswas an applicationfor a groupof variations. A.4-Administrative change-Change in thename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufactureof theASor manufacturerof anovelexcipient A.7-Administrativechange-Deletion of manufacturing sites A.7-Administrativechange-Deletion of manufacturing sites | 18/05/2018 | n/a        |      |                                                                                                                                                                                                                                                     |
| IB/0120          | B.II.f.1.b.1-Stability of FP-Extension of the shelf life of the finished product - As packaged for sale (supported byreal time data)                                                                                                                                                                                                                                              | 04/05/2018 | 20/09/2018 | SmPC |                                                                                                                                                                                                                                                     |
| PSUSA/89/20 1709 | PeriodicSafetyUpdateEUSingleassessment- aliskiren,aliskiren/hydrochlorothiazide                                                                                                                                                                                                                                                                                                   | 12/04/2018 | n/a        |      | PRACRecommendation-maintenance                                                                                                                                                                                                                      |
| IA/0118          | B.I.a.2.a-Changes in the manufacturing process of theAS-Minorchangeinthemanufacturingprocess of the AS                                                                                                                                                                                                                                                                            | 19/01/2018 | n/a        |      |                                                                                                                                                                                                                                                     |
| WS/1026          | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008.                                                                                                                                                                                                                                               | 14/12/2017 | 20/09/2018 | SmPC | StudyF2301evaluatedtheeffectofaliskirenas monotherapyandofthecombinationofaliskirenwith enalaprilcomparedtoenalaprilforcardiovascularmortality                                                                                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Updateofsection5.1oftheSmPCin order toreflect theresultsofstudySPP100F2301(ATMOSPHERE)a multicenter,randomized,doubleblind,parallel group, active-controlled study to evaluate the efficacy and safetyofbothaliskirenmonotherapyand aliskiren/enalapril combination therapy compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV). TheRMP(v13.2)has alsobeen updated to reflect the study results. C.I.4 -Change(s)in the SPC, Labelling or PL due to new quality,preclinical,clinical or pharmacovigilance   | data   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|

<div style=\"page-break-after: always\"></div>

|                  |                                                                                                                                                                                                                      |            |            |                                  | respectively. Statistically significantlyhigherincidencesin the occurrence ofcardiacfailureandischaemicstrokewerealsofoundfor aliskirencompared to enalapril inpatientswith NYHA I/II withhypertension，andintheoccurrenceofchroniccardiac failure and ventricular extrasystole in patients with NYHA III/IVwithhypertension.For the combination of aliskiren and enalapril there were statistically significant differences in the rate of angina unstable compared to enalapril. No clinicallyrelevantdifferences in efficacy orsafetyresults wereobserved inthesubpopulationofelderlypatientswith a history ofhypertension and chronicheartfailure ClassI- II compared to the overall studypopulation.   |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0116        | B.11.b.2.c.1-Change to importer,batch release arrangements andqualitycontrol testingof theFP- Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Not including batch control/testing | 12/10/2017 | 20/09/2018 | AnnexII and PL                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0115          | C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                | 04/10/2017 | 20/09/2018 | SmPC and PL                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| T/0114           | TransferofMarketingAuthorisation                                                                                                                                                                                     | 21/07/2017 | 22/08/2017 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| R/0112           | Renewal of themarketing authorisation.                                                                                                                                                                               | 23/03/2017 | 22/05/2017 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/89/20 1609 | PeriodicSafetyUpdateEUSingleassessment- aliskiren,aliskiren/hydrochlorothiazide                                                                                                                                      | 05/05/2017 | n/a        |                                  | PRACRecommendation-maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| IA/0111/G   | This was an applicationfor a group of variations. A.4-Administrative change-Change in the name and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused inthemanufactureof theASor manufacturerofanovelexcipient A.7-Administrativechange-Deletionof manufacturingsites                                                                                                                                                                                                                                                                                   | 14/11/2016   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0891     | Thiswas an applicationfor avariationfollowing a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. Update of sections 4.2,4.8,5.1 and 5.2 of the SmPC forRasilez and section 4.8,5.1 and 5.2 ofRasilez HCTonthebasisofthecompletedlongterm extendedpaediatricstudyCSPP100A2365E1.The MAHhastakentheoccasion toincludesomeeditorial changesinbothSmPCsand tobettersummarise the informationfromnon-clinicalstudiesinsection5.3of bothSmPCs at the requestofthe CHMP. C.I.4-Change(s)in theSPC,LabellingorPL due to newquality,preclinical,clinical orpharmacovigilance data | 15/09/2016   | 22/05/2017 | SmPC | Thesafety andefficacyofRasilezinchildrenaged6to17 yearshavenotyetbeenestablished.Currentlyavailable data are described in sections 4.8, 5.1, and 5.2,but no recommendationonaposologycanbemade. Aliskirenhasbeenevaluatedforsafetyinarandomised, double-blind,8-weekstudy in267hypertensivepatients aged6to17years,mostlyoverweight/obese,followedby anextensionstudyincluding208patientstreatedfor52 weeks.This study was extendedwith a52-week double- blind,randomisedstudytoevaluate the safety,tolerability andefficacyofaliskirencomparedtoenalaprilin208 paediatrichypertensivepatientsaged6to17years(at baseline intheprevious study).Attheendof thisextension study,changesinmsSBPfrombaselineweresimilarwith aliskirencompared toenalapril(7.63mmHgvs.7.94 mmHg)in thefull analysisset.However,the significance of the non-inferiority testing was not maintained when the analysiswasperformedontheper-protocolset.In addition,due to thepossibility of up-titration if medically necessarytocontrol themsSBP,noconclusioncanbe |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     | drawn on the appropriate posology of aliskiren in patients aged 6 to 17 years. In the8-weekrandomised,double-blind studywith aliskirenmonotherapyin267paediatrichypertensive patients aged 6 to 17 years, mostly overweight/obese, fastingtroughaliskirenconcentrationsatday28were comparableto thoseobservedinotherstudiesinboth adults and children using similar aliskiren doses. In juvenile repeated toxicity studies in rats aliskiren at 100 and300mg/kg/daywas associatedwithhighmortality and severemorbidity.Increasedsystemicexposure toaliskiren (>400-foldhigherin8dayoldratscomparedwithadult rats)was observed.The MDR1geneexpression injuvenile ratswasalsosignificantlylowerwhencomparedtoadult rats.The increased aliskiren exposure in juvenile rats appears to be attributed mainly to lack of maturation of P- gp. There is therefore a potential for aliskiren overexposure   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0890 | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. SubmissionofstudySPP100A2417\"Amulti-database cohortstudyto assess theincidenceratesof colorectal hyperplasia amonghypertensive patients\". C.I.13-Othervariations not specifically covered elsewherein thisAnnexwhichinvolve thesubmission of studies to the competent authority | 15/09/2016 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| WS/0771   | This was an applicationfor a variationfollowing a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. UpdateoftheRMP(v12.3)withregardstoidentified risks，missinginformation,concomitantuse ofother medicines,drug-druginteractions,removalofsafety issues attributed to thenowwithdrawn aliskiren/amlodipine(Rasilamlo)and aliskiren/amlodipine/HCTZ (Rasitrio). C.1.11.b -Introduction of, or change(s) to, the obligations andconditionsof amarketing authorisation,including the RMP-Implementation of change(s)whichrequire tobefurthersubstantiated by newadditional data tobesubmittedby theMAH   | 15/09/2016   | 22/05/2017   | SmPC                             | ThemainchangestotheRMParethedeletionofall informationonthefixedassociationaliskiren/amlodipine (SPA100)and aliskiren/amlodipine/HCTZinview of their withdrawalintheEU,thedeletionofsomerisks and the deletionofthe studyASSESS(CSPP100A2370)from thelist ofstudiesinpost authorizationdevelopmentplanbasedon submissionoftheStudyReportSPA100A\"Antihypertensive Effects and Long-Term Safety of Ali in Elderly Patients\".Section5.1of the SmPC hasbeen also updated to reflectthatinapooled analysisofefficacy andsafetydata from clinical trials up to 12 months duration, there was no statisticallysignificantdifferenceinbloodpressure reductionbetween aliskiren300mgand aliskiren150mgin elderlypatients(≥65years).TheRMPhas alsobeen revised with this submission.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0849   | Thiswas an applicationfor avariationfollowing a worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. Update of sections 4.2,4.5 and5.2of the SmPC in ordertoupdateinformationonfoodeffecton administrationofaliskirenasanalysed instudy SPP100A2413.ThePackageLeafletisupdated accordingly.In addition,the worksharing applicant (WSA)tooktheopportunity tobring thePIin line with thelatestQRD templateversion9.1.                                                                                                                                                                                       | 26/05/2016   | 24/06/2016   | SmPC, Annex II, Labelling and PL | Theefficacyof aliskirenwasshowntobesimilarwhen takeneitherwith alight meal orwithout ameal.Oraluse: Thetablets shouldbe swallowedwholewithsomewater. Rasilezshouldbe takenonce aday,withor withoutfood, preferably atthesame timeeachday.Patientsshould establishaconvenientdailyscheduleofdrugintakeand maintainasteady temporal relationshipwithfood intake. Concomitant intake withfruit juice and/or drinks containing plantextracts(includingherbal teas)shouldbe avoided.                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                  | intendedtoimplementtheoutcomeofaprocedure concerningPSURorPASSortheoutcomeofthe assessment done underA 45/46-Change(s)with newadditional datasubmittedbytheMAH                                                                                                                                                                 |            |            |      |                                |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------|
| PSUSA/89/20 1509 | PeriodicSafetyUpdateEUSingle assessment- aliskiren,aliskiren/hydrochlorothiazide                                                                                                                                                                                                                                               | 14/04/2016 | n/a        |      | PRACRecommendation-maintenance |
| IG/0669/G        | This was an applicationfor a group of variations. A.7-Administrativechange-Deletionof manufacturingsites B.I.a.1.f-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementor additionofasitewhere batch control/testing takes place | 17/03/2016 | n/a        |      |                                |
| WS/0807          | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. C.I.13-Other variations notspecifically covered elsewhereinthisAnnexwhichinvolvethesubmission ofstudiestothecompetent authority                                                          | 28/01/2016 | n/a        |      |                                |
| WS/0793          | This was an applicationfor a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. C.I.3.z -Change(s) in the SPC, Labelling or PL                                                                                                                                        | 14/01/2016 | 24/06/2016 | SmPC |                                |

<div style=\"page-break-after: always\"></div>

|                  | intendedtoimplementtheoutcomeofaprocedure concerningPSURorPASSor the outcomeofthe assessmentdoneunderA45/46-Othervariation                                                                                                                                                                                  |            |            |             |                                                                                                                              |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------|
| WS/0799          | Thiswas an applicationfor a variationfollowing a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. C.I.3.z -Change(s) in the SPC, Labelling or PL intendedtoimplementtheoutcomeofaprocedure concerningPSURorPASSortheoutcomeof the assessmentdoneunderA45/46-Othervariation | 14/01/2016 | 24/06/2016 | SmPC        |                                                                                                                              |
| IA/0105/G        | This was an application for a group of variations. A.7-Administrativechange-Deletion of manufacturing sites A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                         | 10/12/2015 | n/a        |             |                                                                                                                              |
| PSUSA/89/20 1409 | PeriodicSafetyUpdateEUSingle assessment- aliskiren,aliskiren/hydrochlorothiazide                                                                                                                                                                                                                            | 23/04/2015 | 19/06/2015 | SmPC and PL | RefertoScientificconclusions andgroundsrecommending thevariationto termsof theMarketingAuthorisation(s)'for PSUSA/89/201409. |
| IA/0099/G        | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturingsites A.5.b-Administrative change-Change in the name and/or addressof amanufacturer/importerof the finished product, including quality control sites (excludingmanufacturerforbatchrelease)       | 01/04/2015 | n/a        |             |                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| WS/0581   | Thiswas an applicationfor avariationfollowing a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. Submission of thefinal studyreportfor thenon- interventional study CSPP100A2414 - A cohort study toassessvarioussafetyoutcomesinaliskiren initiators using US claims data. C.I.13-Othervariations not specifically covered elsewhereinthisAnnexwhichinvolvethesubmission of studies to the competent authority   | 26/02/2015   | n/a        |                        |           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------|
| WS/0699/G | This was an application for a group of variations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008. C.1.11.z-Introduction of,or change(s) to, the obligations and conditions of a marketing authorisation,including the RMP-Othervariation A.1-Administrativechange-Changeinthename and/oraddressof theMAH                                                                                           | 22/01/2015   | 19/06/2015 | SmPC, Labelling and PL |           |
|           | This was an application for a group of variations. A.7-Administrativechange-Deletionof manufacturingsites A.5.b -Administrative change -Change in the name and/oraddressofamanufacturer/importerofthe                                                                                                                                                                                                                                              | 14/01/2015   | n/a        |                        | IA/0098/G |

<div style=\"page-break-after: always\"></div>

|         | finished product, including quality control sites (excluding manufacturerforbatchrelease)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| WS/0588 | Thiswas anapplicationfor avariationfollowing a worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. C.I.11.b -Introduction of,or change(s) to,the obligations and conditions of a marketing authorisation,including theRMP-Implementation of change(s)which require tobefurthersubstantiated bynewadditionaldatatobesubmittedbytheMAH                                                                                                                                                                                                                                                                       | 18/12/2014 | n/a |     |
| WS/0561 | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Submissionof thefinal studyreportforthenon- interventionalstudyCSPP100A2415-acohortstudy including a nested case-control analysis using data from theUnitedStatesIMSPharMetricsPlusTM healthplanclaims database-assessing the prevalence and incidence of angioedema among patients with hypertension treated with aliskiren or other antihypertensivemedicationsintheUS. Therequestedworksharingprocedureproposed no amendments to thePI. C.I.13 - Other variations not specifically covered | 25/09/2014 | n/a | N/A |

<div style=\"page-break-after: always\"></div>

|           | ofstudiestothecompetentauthority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |             |                                                                                                                               |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------|
| A31/0085  | On17April2013,furtherto theemergenceofnew evidencefromthescientificliteratureondualRAS blockade therapy and given the seriousness of the identified safety concerns, the Italian Medicines Agency(AIFA)initiated areviewunderArticle31of CouncilDirective2001/83/EC,requestingthe PharmacovigilanceRiskAssessmentCommittee (PRAC) toissue a recommendation on thebenefit- riskofdual RASblockade therapythroughthe combineduseofangiotensin-convertingenzyme inhibitors(ACE-inhibitors), angiotensin II receptor blockers(ARBs)or aliskiren and todetermine whether anyregulatorymeasuresshouldbetakenon themarketing authorisations of theproducts involved in this procedure. | 22/05/2014 | 04/09/2014 | SmPC and PL | Forfurtherinformationpleaserefer to theRenin- angiotensin-system (RAS)-acting agents Article 31 referral - Assessment report. |
| IG/0443   | A.5.b - Administrative change - Change in the name and/or addressof amanufacturer/importerof the finishedproduct,including quality control sites (excludingmanufacturerforbatchrelease)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 20/08/2014 | n/a        |             |                                                                                                                               |
| PSUV/0090 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 25/04/2014 | 27/06/2014 | SmPC and PL | RefertoScientificconclusions andgroundsrecommending the variation to terms of theMarketing Authorisation(s)'for PSUV/0090.    |
| WS/0500   | This was an applicationfor a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 20/02/2014 | n/a        |             |                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | C.I.11.b - Introduction of, or change(s) to, the obligations andconditions of a marketing authorisation,including theRMP-Implementation of change(s) which require to be further substantiated bynewadditionaldatatobesubmittedbytheMAH where significant assessment is required                                                                                                                                |            |            |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0481 | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. C.I.11.b -Introduction of,or change(s) to,the obligations andconditions of amarketing authorisation,including theRMP-Implementation of change(s)whichrequire tobefurthersubstantiated bynew additional datatobesubmittedbytheMAH where significant assessment is required | 23/01/2014 | 27/06/2014 | SmPC and Annex II | Proteinuriahasbeenidentifiedasanindependentrisk factorforlossofkidneyfunction orend-stagerenaldisease indiabeticpatients.Earlierstudieshaveindicatedthat proteinuriahasbeen associatedwith increasedrenalaswell as cardiovascular risk.A significant reduction in albuminuriahasbeen achievedwiththeuseofrenin inhibition through aliskiren.Therefore it was hypothesized thataliskirenwouldofferadditionalrenaland cardiovascularprotectionwhen administeredontopof otherRASblockers,leading to thedesignofALTITUDE. ALTITUDEwasadouble-blindplacebo-controlled, randomizedtrialthatenrolledpatientswithType2diabetes andnephropathy asdeterminedbymacro- /microalbuminuria and/oreGFR<60mL/min/1.73m2. Nearlyhalfof thepatientsalsohadsignificant cardiovasculardisease.Patientswithuncontrolled hypertensionwereexcluded.Aliskirenwastestedagainst placebowhenaddedtostandardtherapyincludinganACEI or ARB. The primary objective of theALTITUDE study,was to determinewhether aliskiren,comparedtoplacebo,delays theoccurrenceofcardiovascularandrenal complications when added to conventional treatment in patients with type |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                      |            |     | 2 diabetes athigh riskfor cardiovascular andrenalevents. Aspart of thisprocedure theMAH submitted thefinal CSR of thestudyfulfillingin thisway theobligationmentioned inAnnexIIofallaliskirencontainingproducts.Inaddition theMAHupdated thesection5.1of theSmPCinorder to reflectthefinalresultsoftheALTITUDEstudyincludingthe 1yearsafetyextensionphase. Theefficacyresultsdidnotindicate any advantage of adding aliskiren ontopof standardtherapy including an ACEI orARB.The CHMPconsiders that,thepresented data consistentlysuggestthatthecombinationof inhibitors/blockersoftherenin-angiotensinsystemlowers proteinuria and inadditionincreases therisk of cardiovascularorrenaleventsinhighcardiovascularrisk patients. TheCHMPconcludes thatthecompletedataofthe ALTITUDEstudy do not add any new information to the benefit/riskprofileofaliskirenintheapprovedhypertension indicationandthebenefit/riskbalanceofthealiskiren containingproductsremainspositive.Moreover,itconfirms the appropriateness of the wording regarding the contraindicationfor dual RASblockadeinhigh-riskdiabetic patients, changes that were implemented at the time the preliminary results of ALTITUDE trial were made available. The CHMPconsiders that theproposed updates ofsection 5.1oftheSmPCreflectinanappropriatemanner the   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0480 | This was an application for a variation following a worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. | 23/01/2014 | n/a | TheMAHsubmittedthefinal CSRforAPOLLOstudy. APOLLOstudywasdesignedtodeterminewhether treatmentwith an aliskiren-basedregimen inpart combinedwithamlodipineorhydrochlorothiazidecompared                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| C.I.13-Othervariations not specifically covered elsewherein thisAnnexwhichinvolvethesubmission ofstudiestothecompetentauthority   |
|-----------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                  |            |     | the planned 2000. These low numbers significantly limit interpretation of theresults. TheCHMPconsiders that thepresented datasetdoesnot add new significant information either for safety or efficacy ofaliskirenbecauseofthestudylimitations(premature termination of the study).The safety findings are consistentwiththeknownsafetyprofileofaliskireninthe general hypertensive population. Despite the fact that the studyenrolledavulnerableelderlypopulationwithelevated cardiovascularriskand thattheincidenceofadverseevents andseriousadverseeventswaslowthelimiteddataset does not allow drawing any meaningful conclusion on the safetyprofileofaliskirenwhenusedinelderlypatientsat thehighest approvedstrength(300mg). TheCHMPconsiders thatthisnewdatadoesnotwarrant anySmPCchanges.Thepremature terminationof the APOLLOstudyleavesunsolved theproblemofthedose- responseofaliskireninelderlyhypertensivepatients.This areaofmissinginformationisreflectedintheRMPofthe aliskirencontainingproductsand appropriate pharmacovigilanceactivitiesareemployedinorderto collecttheneeded data.Study CSPP100A2370(ASSESS)is currently planned as a follow up to APOLLO, designed to evaluate the efficacy and safety of alikiren containing products in elderly patients. TheCHMPconcludesthattheworksharingvariationis approvable and the risk/benefit balance of alsikiren containingproductsinthe approved indicationremains   |
|---------|--------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0396 | B.I.a.2.a - Changes in the manufacturing process of theAS-Minor changein themanufacturingprocess | 10/01/2014 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| WS/0467   | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. C.I.13-Other variations not specifically covered elsewherein thisAnnexwhichinvolvethesubmission of studies to the competent authority                                                                                            | 19/12/2013   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0373   | Thiswas an applicationfor avariationfollowing a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR,RMP,FUM/SO,datasubmittedunderArticle 45/46,or amendmentstoreflectaCoreSPC- Change(s)withnewadditional data submittedby the MAH | 24/10/2013   | 03/12/2013 | SmPC and PL | Inapaperpublishedin2011itwasdescribed thatorange andapplejuicereduced theplasmaconcentrations of aliskiren.Thispaperwasreviewedby the MAH andsince theresultswith orange or apple juice werepertinent to the useofaliskiren，anupdatetotheSummaryofProduct Characteristics was proposed in order to add a statement fornotrecommending theconcomitantuseof aliskirenwith orangeorapplejuice. Whencombinedwithallavailabledata(clinicaltrial, literature andpost-marketing),theresultsofthestudy describedinthe abovementionedpapershowedthatthe bioavailabilityofaliskirenismostsensitive toco- administration withfood in general. Theavailableclinicaldatadonotsuggestanadditiveeffect ofdifferenttypesoffoodsand/ordrinks，howeverthe potentialfordecreasedaliskirenbioavailabilityduetothis additiveeffecthasnotbeenstudiedandthereforecannot be excluded. Literaturedataindicate thatvegetablecomponents or extracts may decrease aliskiren bioavailability. Therefore, theCHMPconsidered thatbasedon theavailabledata the |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |      | concomitantconsumptionofvegetablecomponentsor extracts(includingherbal teas and fruit juices)should be avoidedinconjunctionwithaliskirenintake.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0412 | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Update theSmPCsection5.1of all aliskiren containingproducts inordertoreflect therelevant efficacy andsafetyinformationreportedin ASTRONAUT(CSPP100A2368)ClinicalStudyReport. C.I.3.b-Implementation of change(s)requested following the assessmentofanUSR,classlabelling,a PSUR,RMP,FUM/SO，datasubmittedunderArticle 45/46,oramendmentstoreflectaCoreSPC- Change(s) with new additional data submitted by the MAH | 19/09/2013 | 03/12/2013 | SmPC | TheMAH submitted thefinal resultsofASTRONAUTstudy. TheALTITUDEstudywasdesigned toexpand theinitial indication of aliskiren(ALI) exploring whether, in patients withtype2diabetesathighriskforcardiovascularand/or patients with renal events, ALI at a target dose of 300 mg o.d.(compared toplacebo),on top ofconventional treatment(eitherangiotensinconvertingenzymeinhibitor orangiotensinreceptorblocker),reducescardiovascular andrenalmorbidityandmortality.On14December2011, theindependentDataMonitoringCommittee(DMC)ofthe ALTITUDEtrialrecommendedthestudytobehalteddueto futility andpotentialforexcessharminpatientsreceiving ALI(non-fatalstroke,renalcomplications,hyperkalaemia and hypotension in this high-risk study population was observed). Thesubmittedclinicalstudyreportconfirmspreviously submittedandassessedASTRONAUTpreliminaryresults anddidnotshowasignificantbenefitofaddingaliskirento astandard therapyincluding anACEI orARBinpatients hospitalizedwitharecentepisodeofAHF，neitherwith respect to the primary endpoint (CV death or HF re- hospitalization within6 months),nor withrespect tokey secondaryendpoint(firstconfirmedoccurrenceofeitherCV deathorHFrehospitalisationwithin12months).The subgroupanalysisshowedastatisticallysignificant interactionoftreatmentbydiabetesstatusatbaselinefor thecompositeofCVdeathandHFre-hospitalizationwithin 12 months and all-cause mortalitywithin12 months, |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                       |            |            |             | showingexcessofCVevents and theincreasein all-cause death in the aliskiren group in diabeticpatients.In the subgroupofpatientswithdiabetesmellitusthehazardratio was1.64infavourofplacebo(95%ConfidenceInterval: 1.15-2.33), whereas the hazard ratio in the subgroup of patientswithoutdiabeteswas0.69infavourofaliskiren (95%ConfidenceInterval:0.50-0.94);p-value for interaction =0.0003. An increased incidence of hyperkalaemia(20.9%versus 17.5%),renal impairment/renal failure (16.6%versus 12.1%)andhypotension(17.1%versus 12.6%)was observedinthe aliskirengroupcomparedwithplacebo. AsitconcernstheimpactoftheASTRONAUTpreliminary resultson thesafetyprofileof aliskiren andontheproduct information,theCHMPconsidersthatthecurrently approved aliskiren product information is adequately updated in this regard in sections 4.3 and 4.4 (i.e. contraindicationof dual RAASblockadeindiabetic and/or renaldiseasepatients,andawarningfordualblockadeuse in all otherpatients).The CHMPconcludes that the presenteddatadoesn'traiseanyadditionalsafetyconcerns besidesthosealreadyreflectedintheproductinformation and that the overall the benefit/risk of aliskiren containing products remains unchanged.The agreed text included in section 5.1 of the SmPC is considered by the CHMP as appropriately reflecting the relevant findings from   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0407 | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. | 27/06/2013 | 26/07/2013 | SmPC and PL | A drug-drug interactionbetween aliskiren andfurosemide (a loop diuretic)hasbeenpreviouslyidentified.Based on thefactthatloopdiureticsdependontheirrenalexcretion andthesedrugsareactivelysecretedbyrenaltransporters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|         | Updateofsections4.4and4.5oftheSmPCof aliskiren and aliskiren fixed-dose combination productstoinclude a warningstatement concerning theconcomitantuseofaliskirenandtorasemidein patients with heart failure (section 4.4) and to include informationon thepotentialfor drug-drug interactionbetween aliskirenandtorasemide(section 4.5) as per CHMP request expressed in the conclusions ofRasilezHCTPSUR4 and5assessment report. C.I.4-Variationsrelatedtosignificantmodifications of theSPCdue inparticular tonewquality,pre- clinical,clinical orpharmacovigilance data   |            |            |             | of theproximal tubule,it canbeconsidered thatfroma mechanisticpoint of view a drug-drug interactionbetween aliskiren and torasemid(another loop diuretic) is plausible. Noformal aliskiren/torasemiddrug-druginteractionstudy hasbeenperformed.Theavailableclinical datadoesn't showthathigherdosesoftorasemidwereneededwhen taken together with aliskiren.Thepost-marketing data doesn't indicate ahigherincidence ofAEs attributableto a reducedtorasemideeffectwhen aliskirenis takentogether with torasemide.These observations don't support theDDI hypothesisneverthelesssuchinteractioncannotbeout- ruled either. Therefore,theCHMPacceptedtheMAH'sproposalto includeawarningstatementconcerning theconcomitant useof aliskiren andtorasemide inpatientswithheart failure(SmPCsection 4.4)and topresentthe available information on thepotentialfordrug-druginteraction   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0083 | C.I.3.a-Implementation of change(s)requested following the assessment of an USR, class labelling, a PSUR,RMP,FUM/SO,data submittedunderA45/46, oramendmentstoreflectaCoreSPC-Changeswith NOnew additional data aresubmitted by theMAH                                                                                                                                                                                                                                                                                                                                        | 21/06/2013 | 26/07/2013 | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| WS/0375 | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. Updateofsection4.8oftheSmPCofallaliskiren containing products in order to: -include the adverse reactions\"liver disorder\",                                                                                                                                                                                                                                                                                                             | 30/05/2013 | 27/06/2013 | SmPC and PL | Basedonthedataresultedfromasystematicreviewof availableinformationonlivereventsfromthepublished literature,the MAH'ssafetydatabase andclinical trial database，theMAHproposedtheinclusionofADR\"liver disorder\"intheSmPCsection4.8ofallaliskirencontaining products.Thisproposal wasfound acceptableby the CHMP since it was supported by several reported cases of\"liver                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | \"jaundice\"，\"hepatitis\"and\"liver failure”based on severalreported casesof\"liver disorder\" accompanied by clinical symptoms and laboratory evidence ofmarkedhepatic dysfunction,7cases of \"jaundice\"(5 of them with dechallenge+), 2 cases of \"yellow skin\"(both with dechallenge +)and 4 fatal casesof\"hepaticfailure”(including onecaseof\"liver failure fulminant\"with consequent liver transplant). -change the system organ class(SOC)for the ADR \"dizziness\"from Nervous system disorders to Cardiac disorders and theSocfor\"edemaperipheral\"from \"Generaldisordersandadministrationsite conditions\"to\"Cardiac disorders\"inorder to conform totheprimarypathforthemappingoftermsinthe mostcurrentMedDRAversion. ThePackageLeafletwas updated accordingly. C.I.4-Variations related to significant modifications of theSPCdueinparticular tonewquality,pre-   |            |            |                    | disorder\"accompaniedbyclinical symptomsandlaboratory evidence of marked hepatic dysfunction. In addition,at the CHMPrequest,theMAH accepted to include“jaundice”，\"hepatitis”and\"liver failure”asADRs in section4.8oftheSmPCofallliskirencontainingproducts under the system organ class(SOC)\"Hepatobiliary disorders\"with the frequency \"unknown\". The CHMP based itsrequeston7casesof\"jaundice\"(5of themwith dechallenge+),2 cases of\"yellow skin\"(both with dechallenge +)and 4 fatal casesof\"hepaticfailure\" (including one case of\"liver failure fulminant”with consequentliver transplant). Inaddition，changeoftheSOCfortheADR\"dizziness\"from \"Nervoussystemdisorders\"to\"Cardiacdisorders\"andthe SOCforADR\"edemaperipheral\"from\"General disorders and administration site conditions\"to\"Cardiac disorders\" was implemented in order to reflect the latest primary path for the mapping of terms presented in the most current MedDRAversion.   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0374 | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. TheWSA updatedsection4.4.of theSmPCs of all aliskirencontainingproductswithregardtothe combineduseof agents actingon therenin angiotensinaldosteronesystem(dualblockadeof the renin-angiotensin-aldosterone system(RAAS))and the associated risk of symptomatic hypotension.                                                                                                                                                                                                                                                                                                                                                                                                                                              | 30/05/2013 | 27/06/2013 | SmPC and Labelling | Basedonareviewofthepublishedliteratureandavailable clinical trial andpostmarketing data the CHMP aqreedwith theMAH'sconclusion that thereis ahigherriskof hypotension inpatientstakingaliskiren incombinationwith otheragentsactingontherenin-angiotensin-aldosterone system (RAAS) such as angiotensin-converting-enzyme inhibitors(ACEIs)and angiotensin II receptorblockers (ARBs). Therefore,the MAH's proposal to update section 4.4.of the SmPCsofall aliskirencontainingproductswithregard to                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|           | In addition,theMAH tooktheopportunity toupdate thelistof localrepresentativesinthePackage Leaflet. C.I.4-Variationsrelated to significant modifications of theSPCdue inparticular tonewquality,pre- clinical,clinicalorpharmacovigilancedata                                                                                                                                                                                                                                                                                                                                 |            |            |          | thecombineduse of agentsacting on therenin angiotensin aldosterone system(dualblockadeof therenin- angiotensin-aldosterone system(RAAS))and the associated risk of symptomatic hypotension was found acceptablebytheCHMP.                                                                                                                                                                                                                                                                                              |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0287   | This was an application for a variationfollowing a worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. UpdateoftheRMPfor aliskiren containingproducts addressing the obligationsintroduced as aresult of Article20procedure andRasilezR-62/RiprazoR-68 renewal procedure. AnnexIIhasbeenupdated toreflectthatthis commitmenthasbeenfulfilled. C.I.3.z - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR,RMP,FUM/SO,datasubmittedunderA45/46, or amendments toreflect aCoreSPC-Other variation | 21/03/2013 | 17/04/2013 | Annex II | TheMAHsubmittedaconsolidateRMPversionapplicable for aliskiren, aliskiren monotherapy,and its three FDCs in order toaddresstheobligationsintroduced as aresult of Article20procedureandRasilezR-62/RiprazoR-68renewal procedures. TheCHMPconcluded thatRMPversion9adequately describes all thesafety concerns,theplanned pharmacovigilance activities and theinterventionsdesigned toidentify,characterise，prevent orminimisethe risks. Therefore theMAH'sproposaltoremove the above commitmentfromAnnexIIisacceptable. |
| IB/0077/G | Thiswasanapplicationforagroupofvariations. B.II.d.1.z-Change in the specification parameters and/or limits of the finishedproduct-Other variation B.II.d.2.a - Change in test procedure for the finished product-Minorchangestoanapprovedtest                                                                                                                                                                                                                                                                                                                                | 05/03/2013 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|         | procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                   |                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0327 | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Update of sections 4.2,4.8and5.2 of theSmPC in orderto addpharmacokineticandsafetyinformation relatedtopaediatricpopulationfollowingthe assessmentofthestudyCSPP100A2256. C.I.3.b-Implementationofchange(s)requested following the assessment of an USR, class labelling, a PSUR,RMP,FUM/SO,datasubmittedunderArticle 45/46,or amendmentstoreflect aCoreSPC- Change(s)withnewadditional data submitted by the MAH | 17/01/2013 | 18/02/2013 | SmPC              | Basedon theresults of aclinical studyconducted in paediatric population the MAH updated the SmPC in order toconfirm that:basedonthe availabledatainchildren posology recommendations in children cannot be made (SmPCsection 4.2),the safety and pharmacokinetics profiles in children are expected to be similar to the one in adults (SmPCsection 4.8and5.2).TheCHMP agreed with the proposed updates. |
| IG/0248 | C.I.z-Changes(Safety/Efficacy)ofHumanand VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 17/12/2012 | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                          |
| WS/0309 | This was an application for a variation following a worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. This submission presentsthe active treatment phase of the ALTITUDE trial.The MAH required to update theAnnexIIby amending therelevant obligation derivingfromArticle20procedure.Inadditionthe MAH proposed the update of section 5.1 of the SmPC withnewdataoftheALTITUDESTUDY.                                                                                                                                        | 13/12/2012 | 24/01/2013 | SmPC and Annex II | TheMAHsubmittedfinal resultsandstudyreportforthe activetreatmentphaseforALTITUDEtrial.TheMAHwas required toupdatetheAnnexIIby amending theobligation derivingfromArticle20procedureasbelow. TheMAHshall submit thefinal studyreport of the ALTITUDE study,including the1-year safety extension phasecoveringtheresultsoftheactivetreatmentphase relevant to the two differentcut-offdates.               |

<div style=\"page-break-after: always\"></div>

|           | C.I.3.b - Implementation of change(s) requested following the assessmentofanUSR,classlabelling,a PSUR,RMP，FUM/SO,datasubmittedunderArticle 45/46, or amendments to reflect a Core SPC - Change(s)withnewadditionaldatasubmittedbythe MAH                                                                                                                                                                                                                                                                                                                                                                                     |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0280   | This was an application for a variation following a worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. TheMAHproposedtheupdateofsections4.4and 4.5oftheSummaryofProductCharacteristics (SmPC) in order toupdate the informationregarding aliskiren interaction with furosemide following completionof thedrug-to-druginteractionstudy CSPP100A2255. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR,RMP,FUM/SO,datasubmittedunderArticle 45/46,oramendments toreflectaCoreSPC- Change(s)withnewadditional data submittedby the MAH | 13/12/2012 | 24/01/2013 | SmPC        | TheMAHperformed thepresentstudy[CSPP100A2255] withthe aimof assessingwhetherapharmacodynamic (diureticefficacy)interactionexistsbetweenaliskirenand furosemideinheartfailurepatients.Thestudyassessedthe effectofa single(150mg)and multiple doses(150 and 300mg/day)of aliskiren onpharmacokinetics,efficacy and safetyofoncedaily60mgfurosemideatsteadystatein patients with chronic heart failure. Overall, the study data suggestthataliskirenmaydecreasetheefficacyof furosemide.ResultsofstudyCSPP100A2255arethebasis ofaproposalforamodificationofSmPCtexttoupdatethe sections 4.4 and 4.5 of theSmPC. |
| WS/0308/G | Thiswas an applicationfor agroupofvariations following aworksharingprocedure according to Article20ofCommissionRegulation(EC)No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 18/10/2012 | 22/11/2012 | SmPC and PL | WS-0308-Gwassubmittedforagroupofvariations consistingofoneTypeIIvariation andoneTypeIB variationfollowing aworksharingprocedure accordingto Article 20 of Commission Regulation (EC) No 1234/2008. Thesafetyupdateof theSmPCandPackageLeafletwas                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS-0308-Gwassubmittedforagroupofvariations consisting of oneTypeIIvariation and oneTypeIB variationfollowingaworksharingprocedure accordingtoArticle20ofCommissionRegulation (EC) No 1234/2008. Type II variation: Update of sections 4.4 and 4.8 of theSmPCtoincludeinformationon'anaphylactic reactions'reported post-marketing. The Package Leaflet has been updated accordingly.In addition, uponrequestbythe CHMP,theMAH tookthe opportunity to update the SmPC wording related to thehydrochlorothiazidecomponentofthefixed-dose combination.As a consequence,minorchangeshave beenimplementedinsections4.2,4.3and4.4ofthe SmPCand thePackageLeaflethasbeenupdated accordingly. TypeIBvariation:Update of sections 4.4 and4.8 of the SmPC, upon request by the CHMP following the assessment of FU2 026 for aliskiren and FU2 027for aliskiren/HCTZ,toincludefurtherinformation about theADR'angioedema'. C.I.4-Variations related to significant modifications of theSPCdue inparticular to newquality,pre- clinical,clinicalorpharmacovigilancedata C.1.3.a-Implementation of change(s)requested following theassessmentofanUSR,classlabelling,a PSUR,RMP,FUM/SO,data submittedunderA45/46, or amendmentstoreflect aCoreSPC-Changeswith   | basedontheMAH'ssystematicreviewofallavailable informationon anaphylacticreactions associatedwith the useof aliskirenfromclinical studies and theMAH'spost- marketing safety database.A number of cases of 'anaphylactic reaction' could be retrieved from the post- marketing database,ofwhichsixhadnoalternative explanationotherthantreatmentwithaliskiren.The product information of aliskiren-containing products (SPC sections4.4and4.8)was thereforeupdatedwithrelevant information. In addition,sections4.4 and4.8of theSmPCwasupdated bytheMAHtoincludefurtherinformationabouttheADR angioedema'afterarequestbytheCHMPfollowingthe assessmentofFU2026foraliskirenandFU2027for aliskiren/HCTZ. Following theassessmentofthe dataprovided,additional amendmentsnotrelatedto thescopeof thepresent procedurewereimplementedtocorrectsome inconsistenciesinthechangestotheProductInformation approved in the previous WS173 procedure for Rasilez HCT.   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IG/0232   | B.II.b.1.a-Replacementoradditionofa manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                            | 14/11/2012   | n/a   |                               |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------|
| IA/0074/G | This was an applicationfor a group of variations. B.I.b.1.b -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS,starting material/intermediate/reagent-Tightening of specification limits B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits | 23/10/2012   | n/a   | correspondingtestmethod       |
|           | This was an application for a group of variations. B.I.a.1.f-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.b.1.b -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of                                                                                                                                         | 09/10/2012   | n/a   | IG/0220/G specificationlimits |

<div style=\"page-break-after: always\"></div>

| R/0062    | Renewalof themarketing authorisation.                                                                                                                                                                                                                                                                                                             | 19/07/2012   | 23/08/2012   | SmPC, Annex II, Labelling and PL   |                                                                                                       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-------------------------------------------------------------------------------------------------------|
| IG/0209/G | Thiswas an applicationfor a groupof variations. C.I.9.b-Changes to anexistingpharmacovigilance system as described in the DDPS - Change in the contactdetailsoftheQPPV C.I.9.h -Changes to an existingpharmacovigilance system as described in the DDPS - Other change(s) totheDDPSthatdoesnotimpactontheoperationof the pharmacovigilance system | 17/08/2012   | n/a          |                                    |                                                                                                       |
| IG/0206   | A.5.b-Administrative change-Change in the name and/oraddressof amanufacturerof thefinished product,including quality control sites(excluding manufacturer for batch release)                                                                                                                                                                      | 23/07/2012   | n/a          |                                    |                                                                                                       |
| IG/0196/G | Thiswasanapplicationforagroupofvariations. A.7-Administrativechange-Deletionof manufacturing sites B.I.a.1.f-Change in the manufacturer ofASor of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place                           | 13/07/2012   | n/a          |                                    |                                                                                                       |
| WS/0189   | Thiswas anapplicationfor avariationfollowinga worksharingprocedureaccordingtoArticle20of                                                                                                                                                                                                                                                          | 19/04/2012   | 25/05/2012   | SmPC                               | Aliskiren is mainly eliminated through the hepatobiliary route.Renalexcretiononlyaccountsfor0.6%ofthe |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|          | CommissionRegulation(EC)No1234/2008. Update ofsections4.9 and5.2of theSmPCinorder toaddtheinformationonthepharmacokineticsof aliskiren in patients with end stage renal disease receivinghaemodialysisfollowingcompletionofthe studySPP100A2262. C.I.4-Variations related to significantmodifications of theSPCdueinparticular tonewquality,pre- clinical,clinical orpharmacovigilance data                                                                                                                                                                                                                                                                         |            |            |                       | administereddose.No adjustment of the initialdosage is required in patients with mild to severe renal impairment, howevercautionshouldbeexercised inpatientswith severerenalimpairment.TheMAHhasconductedastudy (StudySPP100A2262)tocharacterizethepharmacokinetics andsafetyofaliskireninEnd-StageRenalDisease(ESRD) patientsreceiving haemodialysis(HD).It is concluded that no dose adjustment is needed in patients withESRD.A novel and important finding of the study is that aliskiren cannotbeefficientlyremovedbyHD.Based on the data of StudySPP100A2262,theMAHproposestochangethe section4.9 and5.2of theSmPC.   |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A20/0063 | Article20Review On20December2010,theEuropeanCommission initiatedaprocedureunderArticle20ofRegulation (EC) No 726/2004 for all aliskiren-containing medicinal products authorised in thecentralised procedure and requested the CHMP to assess all the availabledataanditsimpactontheriskbenefit balance for aliskiren-containing medicinal products and togiveitsopiniononwhether themarketing authorisationsfortheseproductsshouldbe maintained,varied,suspended or revoked. Thescope of thereviewwas to assess the risk benefitbalance of all aliskiren-containingmedicinal productsinthe approved indicationofhypertension inlightoftheemergingsafetydatafromthe | 16/02/2012 | 20/04/2012 | SmPC, Annex II and PL | PleaserefertotheAssessmentReport:Rasilez-H-780-A20- 63-AssessmentReport-Article20.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IG/0148/G   | This was an application for a group of variations. C.I.9.e-Changes to anexistingpharmacovigilance system as described in the DDPS - Changes in the majorcontractualarrangementswithotherpersons or organisations involved in the fulfilment of pharmacovigilanceobligations anddescribedinthe DD C.I.9.h-Changes toan existingpharmacovigilance system as described in the DDPS - Other change(s) totheDDPSthatdoesnotimpactontheoperationof   | 22/02/2012   | n/a        | the pharmacovigilance system   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------------------------|
| WS/0191/G   | Thiswas an applicationfor agroup of variations followingaworksharingprocedureaccordingto Article20ofCommissionRegulation(EC)No 1234/2008. Thespecification of the active substance aliskiren has beentightened. Thetestproceduresusedfor aliskirenhavebeen updated. In addition, typographic errors have been corrected in the dossier. All those changes apply to both routes of synthesis of aliskiren(Synthesis B and synthesis C),where    | 16/02/2012   | 16/02/2012 | applicable.                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.I.b.2.b-ChangeintestprocedureforASor startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.1.b - Change in the specification parameters and/orlimits ofanAS,starting material/intermediate/reagent-Tighteningof specification limits B.I.b.2.a -Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure B.1.b.2.e-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0146 | Thiswas an applicationfor avariationfollowing a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. C.1.3.b-Implementation of change(s)requested following theassessmentofanUSR,classlabelling,a PSUR,RMP,FUM/SO,data submittedunderA45/46, oramendments toreflect a CoreSPC-Change(s) withnew additional datasubmittedby theMAH                                                                                                                                                                                                  | 20/10/2011 | 22/11/2011 | SmPC and PL | Arthralgia is a nonspecific symptom which can be associatedwithvariousmedicalconditions.Themost frequentareosteoarthritis，gout，bursitis，infectious diseases,injury,osteomyelitis，andautoimmune diseases. However,it is alsoconsidered thathypersensitivity/allerqic reactionssometimesmanifestwithsystemicinvolvement including arthralgia. Jointswellingisalsoverycommonlyassociatedwiththe abovementionedjointdisorders,orcouldbelinkedto peripheraloedemaortosystemicmanifestationof hypersensitivityreactions. Thisreviewfocused on arthralgia andjointswelling cases where underlyinghypersensitivity reactions likely playeda |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.3.b-Implementation of change(s)requested following the assessment of an USR, class labelling, a PSUR,RMP,FUM/SO,data submittedunderArticle 45/46,or amendmentstoreflectaCoreSPC- Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |            | roleinthedevelopmentofarthralgiaandwhereboth conditions could havebeendue to thedirecteffectof aliskiren. InresponsetotherequestfromCHMP,MAHconducteda comprehensive reviewof all casesof\"Arthrlagia\".Based on thisnewanalysis,CHMPrequestedtheadditionoftheADR \"Arthralgia”insection4.8of aliskirencontainingproduct SmPCs.                                                                                                                                                                                                                                                                                                  |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0145   | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. Updatetosection4.8oftheSmPCtoincludesevere cutaneousadversereactionsincludingtoxic epidermicnecrolysis andoral mucosalreactions, following the assessmentofPSUR5.TheMAH has submitted consequential changes to the Package Leaflet.In addition,minor changes havebeen made in theSection2ofthePackageLeafletwithregards to angioedema for Rasilez, Rasilez HCT, Riprazo and Sprimeo. C.I.3.b-Implementation of change(s)requested following the assessmentofanUSR,classlabelling,a PSUR,RMP,FUM/SO,datasubmittedunderArticle 45/46,oramendmentstoreflectaCoreSPC- Change(s)withnewadditional data submitted by the | 20/10/2011 | 22/11/2011 | SmPC andPL | Toxicepidermalnecrolysis(TEN)isconsideredsevere cutaneous adverse reaction (SCAR) as it is severe, unpredictable, and drug-induced. TEN is characterized by extensivedetachmentoftheepidermisanderosionsofthe mucousmembranes.Inresponse torequestfrom CHMP, theMAHhasconductedcomprehensivereviewinwhich casesofSCARshavebeenidentifiedwherethecausal relationshipwithaliskirencannotberuledoutinthe absence of alternative explanations.Considering the severity of the describedreactions,theCHMPrequested \"SCARs\"including\"TEN\"and\"oral mucosal reactions\"tobe added in section 4.8 of aliskiren containing product SmPC. |
| IG/0088/G | Thiswas an applicationfor a groupof variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/07/2011 | n/a        |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the majorcontractual arrangementswithotherpersons ororganisationsinvolvedinthefulfilment of pharmacovigilance obligations and described in the DD C.I.9.h-Changes to anexistingpharmacovigilance system as described in the DDPS - Other change(s) totheDDPS thatdoesnotimpactontheoperation of thepharmacovigilancesystem                                                                                                                                                                                                                                                   |            |            |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| WS/0139/G | This was an application for a group of variations followingaworksharingprocedureaccording to Article 20of CommissionRegulation(EC)No 1234/2008. Toadd a newmanufacturing site,NovartisGrimsby Ltd, UK, for the intermediates of aliskiren, respectivelyC3 and C6. Togetherwiththischange,severalchangeshave beenintroduced to thereagents,solvents,starting material specifications andbatchsize at the proposedsite. B.I.a.1.a-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS-The proposed manufacturer is part of the same pharmaceuticalgroupasthecurrentlyapproved manufacturer B.I.a.3.a -Change inbatch size(including batch size | 23/06/2011 | 23/06/2011 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | increasecomparedto thecurrentlyapprovedbatch size B.I.b.1.z-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.1.b - Change in the specification parameters and/orlimits ofanAS,starting material/intermediate/reagent-Tightening of specification limits B.I.b.1.c -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its correspondingtestmethod B.I.b.1.d-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Deletionofanon- significantspecificationparameter(e.g.deletion of anobsoleteparameter) B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0098 | This was an application for a variation following a worksharingprocedure accordingtoArticle20of CommissionRegulation(EC)No1234/2008. Updateofsection4.8oftheSmPCtoaddthe AdverseDrugReaction'hypersensitivityreactions' underpost-marketingexperienceasrequestedby CHMPfollowingPSURreview.ThePackageLeaflet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/04/2011 | 23/05/2011 | SmPC and PL | Following thereviewofPSUR5foraliskirenMAHwas requested to consider updating the SmPC to add severe cutaneous adversereactions(SCARs)and arthralgia. ConductedreviewofallcasesofSCARsandofarthralgia didnot demonstrateanevidenceofaclearcausal relationshipbetween theseeventsand aliskirentreatment. However,theanalysisrevealedapossiblerelationship between these events and hypersensitivity.Subsequently |

<div style=\"page-break-after: always\"></div>

|         | hasbeen updated accordingly.In addition,the MAH takes the opportunitytoupdatethecontactdetailsin thePackageLeafletof thelocalrepresentativein Poland. Thisapplicationwassubmittedforagroupof variationsconsistingofTypeIIvariationsfollowinga worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. C.I.4-Variations related to significant modifications of theSPC due in particular to new quality,pre- clinical,clinical orpharmacovigilancedata   |            |            |                        | MAHhasperformedadetailedanalysisofavailabledata. Theevidencepresented is considered to support the inclusionofpost-marketingeventsof\"hypersensitivity\"into theSmPCsection4.8(undesirableeffects)foraliskiren.                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0055 | Thiswas an applicationfor avariationfollowing a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. Updateofsection4.2and5.1of theSmPCtoinclude informationabouttheefficacyandsafetyofaliskiren inelderlyandveryelderlyhypertensivepatients basedondatafrom theAGELESSstudy. C.I.4-Variationsrelated to significant modifications of theSPCdue inparticular tonewquality,pre- clinical,clinical orpharmacovigilance data                           | 14/04/2011 | 23/05/2011 | SmPC                   | AGELESSstudywasconductedinordertospecifically evaluatethesafetyandefficacyof aliskiren and aliskiren/HCT in elderly (>65ys) and very elderly (>75 ys) hypertensivepatients.Overall theresults of this clinical studysupporttheconclusionofapositivebenefit/riskratio intheuseofthealiskiren+HCTZasantihypertensive treatmentofelderlyandveryelderlypatients.However, thereviewofavailabledataalsosuggestsdifferent response to the treatmentofelderlyandveryelderly.Asa result sections 4.2 and 5.1 havebeen updated by including informationabouttheefficacyandsafetyofaliskirenin elderlyandveryelderlyhypertensivepatients. |
| 11/0041 | ThistypeIIvariation concerned anupdateofsection 4.3oftheSummaryProduct Characteristics(SmPC) toremove verapamil from the contraindications,and sections4.4 and4.5of theSmPC,following the CHMPassessmentofFUM015andFUM017,                                                                                                                                                                                                                                                       | 17/03/2011 | 18/04/2011 | SmPC, Labelling and PL | Contraindicationwithregards toconcomitantuse of aliskiren and thehighlypotentP-gpinhibitor ciclosporin and otherpotent P-gp inhibitors(verapamil,quinidine)was introduced on the basis of results from drug-drug interactionstudy.Subsequently,asapartofFUM015MAH                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         | regarding thepotentialforinteractionof aliskiren withverapamil, and the impact of Pgp inhibition on thedistributionofaliskiren.ThePackageLeaflethas been updated accordingly.In addition,the MAH took theopportunitytoimplementminoreditorialchanges in theannexesandtoupdatethelocal representativesin thePackageLeaflet. C.I.4-Variations related to significant modifications of theSPCdue inparticular to newquality,pre- clinical,clinical or pharmacovigilancedata                                                                         |            |            |             | wasrequested toprovide additionalpreclinical data evaluatingthepotential mechanism of theciclosporin and other potent P-gp inhibitor interaction with aliskiren. The MAH appliedfor a typeIIvariationupdatesection4.3of the SmPC to remove verapamil from the contraindications, andsections4.4and4.5of theSmPC,following theCHMP assessmentofFUM015andFUM017,regardingthe potential for interaction of aliskiren with verapamil, and the impact of Pgp inhibition on the distribution of aliskiren.The proposed changes to the product information are acceptable.                                                                                                                                                                                                                                                                                                                     |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0073 | Thiswas an applicationfor avariationfollowing a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. This typeIIvariation concerns anupdate ofsections 4.2 and 4.5 of theSPC inview of the results of study CSPP100A2112investigatingthepotentialinteraction between aliskiren and grapefruit juice inhealthy subjects.ThePackage Leaflethasbeen updated accordingly. C.I.4-Variationsrelated to significant modifications of the SPC due in particular to new quality, pre- clinical,clinicalorpharmacovigilancedata | 17/02/2011 | 18/03/2011 | SmPC        | ThistypeIIvariationconcerns anupdateof section4.5of theSPCinviewoftheresultsofstudyCSPP100A2112 investigatingthepotential interactionbetween aliskiren and grapefruit juice in healthy subjects. Administrationofgrapefruitjuicewithaliskirenresultedina decrease inAuC and Cmax of aliskiren.Co-administration withaliskiren150mgresulted in a61%decrease in aliskiren AUC and co-administration with aliskiren 300 mg resulted in a38%decrease in aliskirenAuC.This decrease islikelydueto an inhibition of organic anion transporting polypeptide-mediateduptakeofaliskirenbygrapefruitjuice in thegastrointestinaltract.Therefore,because of therisk of therapeuticfailure,grapefruitjuiceshouldnotbetaken together with aliskiren. This application was submittedfor a TypeIIvariation followingaworksharingprocedureaccording toArticle20 of CommissionRegulation(EC)No1234/2008. |
| WS/0028 | Thiswas an applicationfor avariationfollowing a worksharingprocedureaccording toArticle20of                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20/01/2011 | 21/02/2011 | SmPC and PL | ThistypeIBvariationconcerns anupdateofsection4.8of the SPC, upon request by CHMP following the assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | CommissionRegulation(EC)No1234/2008. UpdateofSummaryofProductCharacteristicsand Package Leaflet. C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR,RMP,FUM/SO,datasubmittedunderA45/46, or amendments toreflect aCoreSPC-Changeswith NOnewadditionaldataaresubmittedbytheMAH                                                                                                                                                      |            |            |      | ofPSURs4and5for aliskiren,to add theADR'blood creatinineincrease'underpost-marketing experience.The PackageLeaflethasbeenupdated accordingly.Inaddition, the MAH took the opportunity to make some minor editorial changestothesafetyinformationalreadyincludedin section4.8oftheSPC. This applicationwas submitted asaTypeIBvariation following a worksharing procedure according to Article 20 of Commission Regulation(EC) No 1234/2008.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0046/G | Thiswasanapplicationforagroupofvariations. A.4-Administrative change-Change in the name and/oraddressofamanufacturerorsupplierofthe AS,，startingmaterial,reagentorintermediateused inthemanufactureoftheAS B.I.a.1.z-Change in the manufacturer of ASor of a startingmaterial/reagent/intermediateforAS-Other variation A.4-Administrative change -Change in the name and/oraddressof amanufacturerorsupplierofthe AS，startingmaterial,reagentorintermediateused in themanufacture of theAS | 27/01/2011 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| WS/0069   | Thiswas an applicationfor avariationfollowing a worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. This type IB variation concerns an update of sections 4.3,4.4and4.8of theSPC,uponrequestby CHMP                                                                                                                                                                                                                                                            | 16/12/2010 | 21/01/2011 | SmPC | ThistypeIBvariationconcernedanupdateofsections4.3, 4.4 and 4.8 of the SPC, upon request by CHMP following a reviewbythePhvwPoftheriskofangioedemawith aliskiren,to add the new contraindication'hereditary or idiopathic angioedema'andtoaddfurtherinformation abouttheriskofangioedemawithaliskirenadministration.                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | following areviewbythePhvwPoftheriskof angioedema with aliskiren,to add the new contraindication'hereditary oridiopathic angioedema'andtoaddfurtherinformation about theriskof angioedema with aliskiren administration. C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR,RMP,FUM/SO,data submittedunderA45/46, oramendments toreflect a CoreSPC-Changeswith NOnew additional data are submitted by theMAH                                                                                                                                                       |            |     | Theapplicationwassubmittedfor aTypeIBvariation following aworksharingprocedureaccording toArticle20 of CommissionRegulation(EC)No1234/2008. SeescientificdiscussionEMA/H/C/XXXX/WS/0069.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0032/G | Thiswas an applicationfor a group of variations. Toupdate theDetailedDescriptionof the Pharmacovigilance System (DDPS) to version 9.0, to include: -achangeinthedeputyoftheQualifiedPersonfor Pharmacovigilance(QPPV); -achangeinthemajorcontractualarrangements. -administrativechangesnotimpactingtheoperation of the pharmacovigilance system. AnnexII.Bhasalsobeenupdatedwith thelatest wordingasperOctober2010CHMPprocedural announcement. C.I.9.c-Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-upprocedureoftheQPPV C.I.9.e-Changes to an existing pharmacovigilance | 21/12/2010 | n/a |                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | majorcontractualarrangementswithotherpersons or organisations involved in thefulfilment of pharmacovigilanceobligations anddescribedinthe DD C.I.9.h-Changes to an existingpharmacovigilance system as described in the DDPS - Other change(s) totheDDPSthatdoesnotimpactontheoperationof the pharmacovigilance system                                |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0037 | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Update ofSummary ofProductCharacteristics, AnnexII andPackageLeaflet C.I.4-Variations related to significant modifications of theSPCdue inparticular tonewquality,pre- clinical,clinical orpharmacovigilance data | 23/09/2010 | 03/11/2010 | SmPC, Annex II and PL | ThistypeIIvariationconcerned anupdateofsection4.3of theSPCto adda contraindicationfortheconcomitantuse ofaliskirenanditraconazole,andsection4.5oftheSPCto addinformationregarding thisinteractionfollowingthe publication of a study inhealthy subjects.ThePackage Leaflethasbeen updated accordingly.A study inhealthy volunteersshowed thatitraconazole(100mg)increases AUC andCmaxofaliskiren(150 mg)by6.5-fold and5.8- fold,respectively.Therefore,concomitant use of aliskiren and thepotentP-gpinhibitoritraconazoleis contraindicated.In addition,the MAH took the opportunity toupdatetheannexesinlinewiththelatestQRDtemplate (version 7.3). This application was submittedforaTypeIIvariation followingaworksharingprocedureaccordingtoArticle20 ofCommissionRegulation(EC)No1234/2008.See scientificdiscussionEMA/H/C/xxx/WS/0037. |
| II/0042 | This type II variation concerned an update of section 4.8oftheSPC,uponrequestbyCHMPfollowingthe assessmentofPSUR3andPSUR4forRasilez (aliskiren),to include information about the ADR 'peripheraloedema'.ThePackageLeaflethasbeen                                                                                                                      | 22/04/2010 | 02/06/2010 | SmPC and PL           | Peripheraloedemahasbeenreportedwithaliskirenusein thepost-marketingsetting.The detailed analysis of spontaneousreportsshowedthatmanycaseswere confounded by patient medical history or suspect concomitantmedication.Nevertheless,anumberofcases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         | updated accordingly. C.I.3.b-Implementation of change(s)requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46,or amendmentstoreflectaCoreSPC- Change(s) with new additional data submitted by the MAH   |            |            |          | showedapositivedechallengesuchthatacausal relationship to treatment could not be excluded. Therefore, basedon this analysis,and in accordance with CHMP's requests following assessment of PSUR3 and PSUR 4 for Rasilez(aliskiren),theMAH appliedfor a typeIIvariation toupdatethe‘Undesirableeffects'sectionoftheSPCto add the text:\"Post marketing experience: peripheral oedema (frequency unknown)\". The Package Leaflet has also been updated accordingly. Theproposed changes to theproduct information are acceptableandthebenefit/riskbalanceremains unchanged.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0044 | B.I.a.3.a -Change inbatch size (including batch size ranges)ofASorintermediate-Up to10-fold increase compared to the currently approved batch size                                                                                                                       | 23/04/2010 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0043 | B.I.a.3.a -Change inbatch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size                                                                                                                | 23/04/2010 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0045 | B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits correspondingtestmethod                                                                   | 13/04/2010 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0040 | Updateof theDetailedDescriptionofthe Pharmacovigilance system(DDPS).                                                                                                                                                                                                     | 18/02/2010 | 30/03/2010 | Annex II | Withthisvariation theMAHsubmittedanewversionof the DDPS(core version8.0 and product specific version6.0)in accordancewiththecurrentPharmacovigilanceguideline.                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|         | UpdateofDDPS(Pharmacovigilance)                                                                                                                                    |            |            |                        | Afterassessing thedocumentation theCHMPconcluded thatthe submittedDDPScontained all requiredelements.                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0036 | Additionofanalternativecontainerclosuresystem (PCTFE/PVC blister)for Rasilez 150 mg and 300 mg film-coated tablets. Newpresentation(s)                             | 19/11/2009 | 03/12/2009 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0039 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                   | 24/07/2009 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0038 | IA_11_a_Change inbatch size of active substance or intermediate - up to 10-fold                                                                                    | 24/07/2009 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0037 | IA_11_a_Change in batch size of active substance or intermediate-upto10-fold                                                                                       | 24/07/2009 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| I1/0035 | Update of SPC section 5.1 to delete the existing sentencerelating toelevatedplasmareninactivity andcardiovascularoutcomes. UpdateofSummaryofProductCharacteristics | 19/03/2009 | 22/04/2009 | SmPC                   | ThefollowingsentencehasbeendeletedfromSPCsection 5.1basedonthefactthatcurrentlynodataareavailableto directly link the reduction in renin activity induced by aliskirenwitheffectsoncardiovascularoutcomes:\"Elevated PRAhasbeenindependentlyassociatedwithincreased cardiovascularriskinhypertensiveandnormotensive patients.\" as currently there is no evidence available proving that changes in renin activity induced by antihypertensive drugs might have an important role in cardiovasculardisease. |
| I/0034  | Update of SPC section 4.4 to include a warning of events of renal dysfunction inat-riskpatients and to amendtheexistingtextforrenalarterystenosis                  | 19/02/2009 | 03/04/2009 | SmPC and PL            | Foraliskiren，casesofrenaldysfunctionwithrelevant occurrencewerereported inthepostmarketinguse(PSUR 1 and PSUR 2).                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         | followingtheCHMPassessmentofPSURs.SPC section4.8hasbeenupdatedrelatingtoevents of renal dysfunction and acuterenalfailure duringpost- marketingexperience.Thepackageleafethasbeen amended accordingly. UpdateofSummaryofProductCharacteristicsand PackageLeaflet   |            |            |             | Followingevaluationof theavailablepostmarketingdata, theCHMPconcluded toadd a warning toSPCsection4.4 thatcaution should be exercisedwhen aliskiren is given in thepresence of conditionspre-disposing tokidney dysfunction such as hypovolemia (eg. due to blood loss, severe orprolonged diarrhea,prolongedvomiting,etc.), heart disease,liverdisease orkidneydisease.Acuterenal failure,reversibleupondiscontinuation of treatment,has beenreported in at-riskpatientsreceiving aliskiren inpost- marketing experience..In the event that any signs of renal failure occur, aliskiren should be promptly discontinued. Furthermore,SPCsection4.8was also amended.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0033 | UpdateofSPCsection4.5toincludeastatement regarding the potential interaction with non-steroidal anti-inflammatory agents(NSAIDs).Thepackage leaflet has been amended accordingly. UpdateofSummaryofProductCharacteristicsand PackageLeaflet                        | 19/02/2009 | 03/04/2009 | SmPC and PL | TheMAHwasrequested toaddastatementregarding the potentialforinteractionbetweenNSAID'sandagentsacting ontheReninAngiotensinSystem toSPCsection4.5.As with other agents actingontherenin-angiotensinsystem, NSAIDsmayreduce theanti-hypertensiveeffectof aliskiren.In some patientswith compromisedrenal function (dehydratedpatients orelderlypatients)aliskirengiven concomitantly with NSAIDs may result in further deteriorationofrenalfunction,includingpossibleacute renalfailure,whichisusuallyreversible.Thereforethe combination of aliskiren with anNSAIDrequirescaution, especially in elderly patients. The package leaflet has been amended accordingly.    |
| II/0032 | UpdateofSPCsections4.3and4.4toincludea contraindication on the use in patients with prior historyofangioedemaandawarningofangioedema type reactions as for other agents acting on the renin-angiotensinsystemrespectively,followingthe                             | 19/02/2009 | 03/04/2009 | SmPC and PL | Foraliskiren,casesofangioedemawithrelevantoccurrence werereported in thepostmarketinguse.Following the assessmentofthe availabledata,the CHMPconcluded that acontraindicationforpatientswithahistoryofangioedema with aliskiren is needed.In addition, a warning of                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | CHMPassessmentofPSURs.Furthermore,SPC section4.8hasbeenrevisedregarding angioedema casesand thePackageLeaflethasbeenupdated in accordancewiththeSPCchanges. UpdateofSummaryofProductCharacteristicsand Package Leaflet                                                                                                                                                                                                                                                                                                                                                                             |            |            |                        | angioedema-typereactions asforother agents acting on therenin-angiotensinsystemhasbeen added toSPC section4.4recommendingthatpatientswithoutaprevious historywho suffer angioedemawith aliskirenshould discontinuetreatmentandcontacttheirdoctor. Furthermore,theterm\"angioedema\"hasbeenaddedas a rare adverse drugreaction toSPCsection4.8.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0031 | Updateofor change(s)tothepharmaceutical documentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 25/09/2008 | 02/10/2008 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0026 | Update ofSPCsection 4.3\"Contraindications\"and section 4.5\"Interactions\"following new information froma cyclosporine drug-druginteractionstudy (SPP100A2106),whichwassubjecttoaFollow-Up Measure.Furtherrevisionswereintroducedto sectionSPCsections4.4\"WarningsandPrecautions for use\"and 4.5.Thepackageleaflethasbeen amended accordingly.In addition,minor corrections havebeenincluded intherelevantsectionsofSPC, labellingandpackageleafletwithregardtothe active substance(aliskirenhemifumarate)and also forPLsection5. UpdateofSummaryofProductCharacteristics, LabellingandPackageLeaflet | 24/07/2008 | 28/08/2008 | SmPC, Labelling and PL | Theresultsof the cyclosporineinteraction study in14 subjectsshowed thatconcomitantcyclosporine administration increasedAuC4.5to5.5foldwithalower doseof aliskiren(75mg)than theauthorisedstrengths (150and300mg).Alsocyclosporinemarkedlyincreased aliskiren t1/2. Hence, there is concern that the increase in AUCwouldbesubstantiallyhigherwiththeapproved aliskiren dosage,even exceeding the highest dose tested in humans.An additional concern is that aliskiren might distributetotissuesfrom which the medicinalproduct is normallyabsentinpresenceofaP-gpinhibitor,orpresetat lowlevelsbecauseof the activityofP-gp.Nonclinical and clinicaldataconvergetoshowthatP-gpisamajor determinant of aliskirenbioavailability.In addition, literaturedatashowthatP-gpmediatestissueuptakeofa varietyofP-gpsubstratesandthatP-gpinhibitorscan markedlyincreasethetissue-to-plasmaconcentration ratios. Given theverylimitedsafety data atincreasedexposure, |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                                                                                                 |            |            |      | and theriskforverylargeincrease intissueexposure,the CHMPconcluded thattheco-administrationofcyclosporine and aliskiren poses serious safety concerns.Therefore,a contraindicationfortheconcomitantadministrationwith cyclosporine, a highly potent P-gp inhibitor, as well as with other potent Pg inhibitors(verapamil,quinidine）is consideredessential.Moreover,due totheriskforhigher increase in tissue exposure than in plasma, caution should be advised during co administration with moderate P-gp inhibitors (ketoconazol, itraconazol, clarithromycin, telithromycin, erythromycin, amiodarone).                                                                                                                                                                                                                                                                                                                              |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0029 | UpdateofSPCsection5.1\"Pharmacodynamic Properties\"withefficacy datafroma clinical study (study SPP100C2201)in patients with nephropathy. UpdateofSummaryofProductCharacteristics | 30/05/2008 | 09/07/2008 | SmPC | StudySPP100C2201,a6monthlyrandomised,double- blind,placebo-controlledstudyinvestigatedtheeffectsof aliskiren(150mg / 300mg) on proteinuria in 599 patients withhypertensionandTypeII2diabetesmellitusinwhom blood pressure had been previously controlled by means of an angiotensin receptor blocker (losartan) in combination withtheoptional useofotherantihypertensivedrugs (hydrochlorothiazide and/or amlodipine).The addition of 300mgaliskirenachievedanaveragereductioninthe urinary albumin to creatinine (UACR) ratio of 12 mg/mmol (from58to46mg/mmol)comparedtoplacebo.Aliskiren didnotinduce anysignificanteffect onbloodpressure or affectestimatedGFRundertheseconditions.Theclinical relevance of areduction in UACR isnot established in the absence of an effect on blood pressure. Furthermore, aliskirenwasassociatedwithanincreasedfrequency(4.2% vs.1.9%for placebo) in serumpotassium concentration(? 6 mmol/l). |
| II/0028 | Updateof theSPCsection4.4 and5.1following new                                                                                                                                   | 30/05/2008 | 09/07/2008 | SmPC | Study SPP100A2313, a 12-week double-blind, randomised,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|         | informationfromastudy(SPP100A2313)inpatients with heart failure. UpdateofSummaryofProductCharacteristics                                                   |            |            | placebo-controlled, 2-arm study of aliskiren 150 mg od added tostandard therapyinpatientswithstableheart failureevaluatedtheoverallsafetyandtolerabilityof aliskiren 150 mg when given in addition to standard therapy in hypertensive patients with stable heart failure. Thestudyincluded302patientswithmildtomoderate heart failure. Additionof150mgaliskirenshowedareductionofBNP levelsby25%,although theclinicalsignificanceof this reduction is unknown.No statistically significant differences insigns andsymptomsofheartfailurewerefound and overallgradingofpatientsaccordingtoNYHAclassification remained unchanged.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0030 | Updateofor change(s)to thepharmaceutical documentation                                                                                                     | 30/05/2008 | 11/06/2008 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0012 | IB_10_Minor change in the manufacturing process of theactivesubstance IB_12_b_02_Change in spec.ofactive subst./agent inmanuf.ofactivesubst.-testparameter | 31/01/2008 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0027 | IA_32_a_Changeinbatchsizeofthefinishedproduct -up to10-fold                                                                                                | 18/01/2008 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0023 | IB_33_Minorchangeinthemanufactureofthe finished product                                                                                                    | 04/01/2008 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0022 | IB_O7_c_Replacement/add.ofmanufacturing site: Allothermanufacturingoperationsex.batchrelease                                                               | 04/01/2008 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | IA_07_a_Replacement/add.of manufacturing site: Secondarypackaging site IA_07_b_01_Replacement/add. of manufacturing site:Primarypackagingsite-Solidforms   | 23/11/2007   | n/a   | IA/0024   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------|
|         | IB_12_b_02_Change in spec.of active subst./agent in manuf.of active subst.-testparameter                                                                   | 15/11/2007   | n/a   | IB/0002   |
| IB/0001 | IB_12_b_02_Change in spec.of active subst./agent inmanuf.ofactivesubst.-testparameter                                                                      | 15/11/2007   | n/a   |           |
| IA/0020 | IA_11_a_Change inbatchsize of active substance or intermediate-upto10-fold                                                                                 | 12/11/2007   | n/a   |           |
|         | IA_11_a_Change inbatch sizeof active substance or intermediate - up to 10-fold                                                                             | 12/11/2007   | n/a   | IA/0019   |
|         | IA_11_a_Change inbatchsize of active substance or intermediate-upto10-fold                                                                                 | 12/11/2007   | n/a   | IA/0018   |
|         | IA_11_a_Changeinbatchsizeofactivesubstanceor intermediate - up to 10-fold                                                                                  | 12/11/2007   | n/a   | IA/0017   |
|         | IA_11_a_Change inbatch size of active substance or intermediate-upto10-fold                                                                                | 12/11/2007   | n/a   | IA/0016   |
| IA/0015 | IA_11_a_Change inbatch size of active substance or intermediate-up to10-fold                                                                               | 12/11/2007   | n/a   |           |
|         | IA_11_a_Change inbatch sizeof active substance or intermediate -up to 10-fold                                                                              | 12/11/2007   | n/a   | IA/0014   |

<div style=\"page-break-after: always\"></div>

| IA/0013   | IA_11_a_Change in batch size of active substance or intermediate -up to 10-fold   | 12/11/2007   | n/a   |
|-----------|-----------------------------------------------------------------------------------|--------------|-------|